Evidence map›Paper›PMID 39074963›Full record

ArticleJournal for immunotherapy of cancer2024

Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.

Atish Mohanty, Michelle Afkhami, Amanda Reyes, Rebecca Pharaon, Holly Yin, Haiqing Li, Dana Do, Diana Bell, Arin Nam, Sue Chang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. BRAF mutation and tumor immune microenvironment in new era.American journal of cancer research · 2026
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Atish MohantyCity of Hope Comprehensive Cancer Center, Monrovia, California, USA.ORCID http://orcid.org/0000-0003-1464-3165
Michelle AfkhamiDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Amanda ReyesDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Rebecca PharaonDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Holly YinDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Haiqing LiComputational & Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Dana DoDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Diana BellDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Arin NamDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Sue ChangDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Thomas GernonDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Robert KangDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Arya AminiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California, USA.
Sagus SampathDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, California, USA.
Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Raju PillaiDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Vicky VillaflorDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
Ellie MaghamiDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Erminia MassarelliDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA emassarelli@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study summarizes the potential use of immunotherapy for MATERIALS AND

methodsPTC cases with available formalin-fixed paraffin-embedded archived tumor tissue were identified. RNA was extracted from the tumor tissue and analyzed by NanoString to evaluate their immune gene expression profile. Immunohistochemistry was used to determine the expression of immune suppressive genes and lymphocytic infiltration into the tumor tissue. Thyroid cancer cell lines (MDA-T32, MDA-T68, MDA-T85, and MDA-T120) were used to determine the correlation between the BRAF inhibition and CD274 expression.

resultsThe study found that PTC cases with

conclusionsThese findings suggest that PTC cases with

Indexed as

Biomarkers, TumorProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid NeoplasmsAdultCell Line, TumorFemaleHumansImmunotherapyMaleMiddle AgedMutationBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafCD4-Positive T-LymphocytesImmune Checkpoint InhibitorsTumor Microenvironment

Identifiers

PMID39074963
PMCPMC11288153

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.